Analysis Group Welcomes New Affiliates, Announces Staff Promotions
Date:March 06, 2014
Boston -- Analysis Group, a leading provider of economic, financial, and business expertise to law firms, corporations, and government agencies, announces the promotions of professional staff and welcomes nine new affiliates to the firm.
"These individuals bring a diverse set of skills and experiences to all of our practice areas," said President and CEO Martha S. Samuelson. "We are pleased to recognize their efforts, and we look forward to their continued contributions to the success of our clients and the firm."
Roberts W. Brokaw III is an independent consultant with three decades of investment banking experience in the context of equity, debt, mergers, and strategic restructurings. He also has special expertise in equity-linked securities, preferred stock, high-yield debt, investment banking practices, fairness opinions, and securities covenants, as well as experience as a coverage banker in the utility and transportation industries. Over the past decade, he has testified and authored expert reports in Delaware Chancery Court, U.S. bankruptcy courts, and various U.S. district and state courts, as well as in private arbitrations.
Myron S. Glucksman is an independent expert who advises investment banks, law firms, and companies on CDOs, RMBS, SIVs, ABS, ABCP, and other structured finance products. A former managing director of Citigroup's Corporate and Investment Bank, Mr. Glucksman has more than 30 years of investment banking and legal experience in a broad range of securities, corporate, and consumer matters.
Deborah Haas-Wilson, the Marilyn Carlson Nelson Professor of Economics at Smith College, is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities.
Stephen J. Hoch -- the Laura and John J. Pomerantz Professor in Marketing at The Wharton School, University of Pennsylvania -- focuses his research on retail merchandising, assortment, pricing, and promotion strategy. He consults to leading consumer goods manufacturers and retailers around the world, helping them to focus retail strategies and improve pricing and merchandising tactics via point-of-sale data. Professor Hoch has extensive experience authoring expert reports and testifying at deposition and trial in litigation matters involving deceptive advertising; Lanham Act issues; patent, copyright, and trademark infringement; breach of contract; transfer pricing; and antitrust claims.
William McGivney, a principal at McGivney Global Advisors, is an expert in health care coverage and reimbursement policy, and in drug and medical device regulatory policy. Dr. McGivney's work focuses on developing strategies for coverage policies; positioning in clinical guidelines, pathways, compendia, and pricing; and assessing the type, quality, and quantity of data necessary to achieve acceptance by clinicians. He regularly consults to pharmaceutical and biotech companies regarding the positioning of drugs, biologics, and devices in the marketplace.
Robert P. Navarro, a clinical professor at the University of Florida's College of Pharmacy and president of Navarro Pharma LLC, is a managed care expert with more than 30 years of experience. Professor Navarro serves as a consultant and expert to health care, pharmaceutical company, and law firm clients on topics including drug pricing and contracting, drug formulary access and reimbursement, and drug benefit outcomes.
Russell F. Peppet, a partner at Park Avenue Equity Partners, is an expert in cost accounting in the mutual fund industry and brings with him more than 40 years of experience in finance and equity investment. He has provided expert testimony and been deposed in several Section 36(b) cases, including Gartenberg v. Merrill Lynch Asset Management and Bennett v. Fidelity Management & Research. He has also participated in and managed consulting engagements in the areas of financial management, cost accounting, and budgeting.
David J. Reibstein -- the William Stewart Woodside Professor of Marketing at The Wharton School, University of Pennsylvania -- focuses his research on topics such as competitive marketing strategies, metrics, and product line decisions. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.
Daniel O. Scharfstein, a professor of biostatistics at the Johns Hopkins Bloomberg School of Public Health, is an expert in the design, monitoring, and analysis of randomized clinical trials, as well as observational studies. His research focuses on statistical methods to account for selection bias in clinical studies primarily caused by missing or censored data, non-compliance, or non-random treatment assignment. He regularly consults with the pharmaceutical industry on statistical issues related to the regulatory approval of drugs and devices, and has served as an expert and provided depositions in a number of legal cases involving the safety and efficacy of drugs and devices.
New Managing Principals and Principals
Earlier in the year, Analysis Group promoted three consultants to managing principal and three consultants to principal.
Managing Principal Adam Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards.
Managing Principal Mark Howrey has more than 15 years of experience providing consulting assistance to clients, with a focus on finance, securities, and damages analyses in complex litigation. He has conducted analyses of market efficiency, examined loss causation and materiality, calculated damages, and assessed settlements in numerous securities matters involving alleged violations of Sections 10b-5, 11, and 12.
Managing Principal Alan G. White, Ph.D., focuses on antitrust, intellectual property, general commercial litigation, and tax/transfer pricing matters in a range of industries, with a particular interest in health care issues. He has worked on matters involving allegations of false advertising and breach of contract; investigations into alleged product fraud and off-label promotion of prescription drugs; and the economic impact of generic entry and substitution.
Principal George Kosicki, Ph.D., specializes in applied microeconomics and has consulted in the areas of antitrust, mergers and acquisitions, agricultural economics, labor economics, corporate finance, and commercial damages. He has also served as an expert witness on market definition, liability, and damages issues.
Principal David W. Sosa, Ph.D., specializes in the economics of network industries, law and economics, and industrial organization. He has consulted to telecommunications and electric utility clients on a broad range of litigation and regulatory issues, including industry restructuring, technical standardization, benchmarking, mergers and acquisitions, market power analysis, and competitive strategy.
Principal Robert L. Vigil, Ph.D., specializes in the application of economics and finance to complex commercial litigation matters. His work includes the estimation of damages in intellectual property and breach of contract cases; the evaluation of patented drug products' commercial success in connection with generic manufacturers' Abbreviated New Drug Application submissions to obtain early market entry; and the analysis of issues related to the granting of permanent injunctions.
New Vice Presidents
The firm has promoted nine consultants to vice president.
In Boston: Xinyu Ji specializes in the application of economics and finance to litigation matters in the areas of mergers and acquisitions, valuation, financial instruments, and tax, with recent focus on M&A bid premiums, public and private benefits of control, deal terms, negotiation processes, and consequences of breaching non-disclosure or standstill agreements. In Chicago: Rebeccah Weiss Filsoof has conducted economic and financial analyses and managed case teams in support of academic and industry experts in a broad range of cases, including finance and securities, antitrust, and general business litigation. Divya Mathur, Ph.D., focuses on conducting analyses, managing case teams, and supporting academic affiliates in a variety of antitrust, intellectual property, securities, and general commercial litigation matters. In Menlo Park: Asta D. Sendonaris, Ph.D., has experience working on major antitrust, valuation, intellectual property matters, and insurance cases, as well as non-litigation health care consulting projects. In Montreal: Marissa Ginn, Ph.D., specializes in applying microeconomic and econometric techniques in both litigation and non-litigation contexts, and has led large teams in antitrust, commercial damages, and intellectual property cases within several industries, including chemicals, telecommunications, finance, pharmaceuticals, and technology. Annie Guérin focuses on pharmacoeconomics and econometrics projects, and conducts pharmacoeconomic analyses using large insurance claims databases. In New York: Dendy Macaulay, Ph.D., applies statistics and econometrics to health outcomes research, focusing on retrospective claims analyses, patient chart reviews, clinical trial data analyses, economic modeling, and health economics and outcomes research strategy. Jipan Xie, Ph.D., M.D., has extensive experience in health economics and outcomes research, with significant work on economic evaluations, health technology assessments both in the U.S. and global markets, and comparative outcomes research using clinical trial and real-world data. In San Francisco: Elizabeth Stone, Ph.D., specializes in securities and antitrust litigation matters, and has conducted economic analyses of market efficiency, loss causation, damages exposure, and price overcharges.
New Managers and Senior Economists
Analysis Group has promoted 15 consultants to manager or senior economist.
In Boston: Daniel Andersen, Rajeev Ayyagari, Ph.D., Ryan Booth, Ph.D., and Jason Gilbody. In Dallas: Thomas McGahee, Ph.D. In Denver: Kevin Gallagher. In Los Angeles: Hristina Bojadzieva and Jerome Kim. In Montreal: Martin Cloutier, Anne Catherine Faye, and Dominick Latremouille-Viau. In New York: Luke D. Archer, Gourab De, Ph.D., and Peter Gerstein. And in Washington, D.C.: Samuel H. Kina, Ph.D.
About Analysis Group
Analysis Group's more than 500 professionals provide economic, financial, and business strategy consulting to leading law firms, corporations, and government agencies. The firm's 11 offices are located nationally in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, and Washington, D.C.; and internationally in Montreal and Beijing.